Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureStephen L. Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Jee Hyun Kim, Binh Pham, Jung Yong Hong, Dirk-Thomas Waldschmidt, Donatella Marino, René Gerolami, Adam M. Burgoyne, Robert John Walsh, Jens U. Marquardt, Ugochinyere Emeribe, Kavitha Balaji, Boris Baur, Lorenza Rimassa
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2025.02.006 · 2025
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
10.1016/j.jhep.2024.08.028 · 2025
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
10.1056/evidoa2100070 · 2022
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
10.1016/s0140-6736(25)00403-9 · 2025
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab
10.1002/cam4.3116 · 2020
Treatment and the prognosis of hepatocellular carcinoma in Asia
10.1111/liv.15130 · 2022
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.jhep.2025.03.033 · 2025
Real-world experiences using atezolizumab + bevacizumab for the treatment of unresectable hepatocellular carcinoma: a multicenter study
10.3390/cancers17111814 · 2025
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
10.1002/hep.32468 · 2022
Effectiveness and safety of nivolumab in Child–Pugh B patients with hepatocellular carcinoma: a real-world cohort study
10.3390/cancers12071968 · 2020
Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases
2025
Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150
2024
CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
10.1016/j.jhep.2021.04.047 · 2021
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE trial final results
10.1200/jco.2025.43.4_suppl.587 · 2025
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
10.1016/j.annonc.2024.02.005 · 2024
Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants with unresectable hepatocellular carcinoma from the combined China extension and global cohorts in the Phase 3 HIMALAYA study
10.1016/j.annonc.2025.08.2124 · 2025
Systemic treatment of HCC in special populations
10.1016/j.jhep.2020.11.026 · 2021
Early safety results from the phase 3b SIERRA study of durvalumab and tremelimumab as first-line treatment for participants with unresectable hepatocellular carcinoma and a poor prognosis
10.1159/000549955 · 2025
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
10.1016/s0140-6736(23)00961-3 · 2023
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
10.1097/hep.0000000000001385 · 2026
Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction
10.1001/jamaoncol.2024.2166 · 2024
Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
10.1177/17588359221148541 · 2023
Real-world outcomes of combination immunotherapy in patients with Child–Pugh class B hepatocellular carcinoma
2026
Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?
10.1016/j.livres.2024.09.002 · 2024
No additional external references are available.